Assignee
OVID THERAPEUTICS INC
US51 patents
Top patents by PatentIndex Score
US11395817B2Jul 26, 2022
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC8 citations94
US10603308B2Mar 31, 2020
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC17 citations94
US9446028B2Sep 20, 2016
Methods of increasing tonic inhibition and treating fragile X syndrome and angelman syndrome
OVID THERAPEUTICS INC26 citations94
US9351968B1May 31, 2016
Methods of treating developmental disorders using pipradrol
OVID THERAPEUTICS INC24 citations94
US9339495B2May 17, 2016
Methods of increasing tonic inhibition and treating secondary insomnia
OVID THERAPEUTICS INC26 citations94
US10799485B2Oct 13, 2020
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC8 citations92
US10363246B1Jul 30, 2019
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC13 citations92
US9682069B2Jun 20, 2017
Methods of treating Dravet syndrome
OVID THERAPEUTICS INC19 citations92
US9717716B2Aug 1, 2017
Methods of sedation during critical care treatment
OVID THERAPEUTICS INC16 citations91
US9399034B1Jul 26, 2016
Methods of sedation during critical care treatment
OVID THERAPEUTICS INC20 citations91
US10188635B2Jan 29, 2019
Use of gaboxadol in the treatment of tinnitus
OVID THERAPEUTICS INC5 citations84
US10071083B2Sep 11, 2018
Use of gaboxadol in the treatment of tinnitus
OVID THERAPEUTICS INC11 citations84
US9801864B2Oct 31, 2017
Methods of increasing tonic inhibition and treating secondary insomnia
OVID THERAPEUTICS INC7 citations84
US9744159B2Aug 29, 2017
Methods of treatment Rett syndrome
OVID THERAPEUTICS INC9 citations84
US11291658B2Apr 5, 2022
Use of gaboxadol in the treatment of diabetes and related conditions
OVID THERAPEUTICS INC2 citations73
US11096929B2Aug 24, 2021
Methods of treating developmental disorders with gaboxadol
OVID THERAPEUTICS INC3 citations73
US10813918B2Oct 27, 2020
Use of Gaboxadol in the treatment of diabetes and related conditions
OVID THERAPEUTICS INC3 citations73
US10765646B2Sep 8, 2020
Methods of treating developmental encephalopathies
OVID THERAPEUTICS INC2 citations73
US10653652B2May 19, 2020
Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
OVID THERAPEUTICS INC5 citations73
US10195165B2Feb 5, 2019
Methods of treating Prader-Willi syndrome
OVID THERAPEUTICS INC2 citations73
US9913833B2Mar 13, 2018
Methods of treating developmental disorders using pipradrol
OVID THERAPEUTICS INC4 citations73
US9827233B1Nov 28, 2017
Methods of treating behavioral syndromes using pipradrol
OVID THERAPEUTICS INC4 citations73
US9610261B2Apr 4, 2017
Methods of treating Prader-Willi Syndrome
OVID THERAPEUTICS INC3 citations73
US10111865B2Oct 30, 2018
Methods of sedation during critical care treatment
OVID THERAPEUTICS INC2 citations71
US10813899B2Oct 27, 2020
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
OVID THERAPEUTICS INC2 citations68
US12465597B2Nov 11, 2025
Methods of treating developmental disorders with gaboxadol
OVID THERAPEUTICS INC0 citations62
US12144801B2Nov 19, 2024
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC0 citations62
US12109201B2Oct 8, 2024
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC0 citations62
US11918551B2Mar 5, 2024
Methods of treating seizure disorders and Prader-Willi syndrome
OVID THERAPEUTICS INC0 citations62
US11918563B1Mar 5, 2024
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC0 citations62
US11903930B2Feb 20, 2024
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC0 citations62
US11806336B2Nov 7, 2023
Methods and compositions for treatment of epileptic disorders
OVID THERAPEUTICS INC0 citations62
US11771671B2Oct 3, 2023
Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
OVID THERAPEUTICS INC0 citations62
US11761006B2Sep 19, 2023
Use of MIR101 or MIR128 in the treatment of seizure disorders
OVID THERAPEUTICS INC0 citations62
US11690829B2Jul 4, 2023
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
OVID THERAPEUTICS INC0 citations62
US11364228B2Jun 21, 2022
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
OVID THERAPEUTICS INC0 citations62
US11278529B2Mar 22, 2022
Methods for treating aggression associated with Alzheimer's disease
OVID THERAPEUTICS INC0 citations62
US11130952B2Sep 28, 2021
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
OVID THERAPEUTICS INC0 citations62
US11090293B2Aug 17, 2021
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
OVID THERAPEUTICS INC0 citations62
US10925879B2Feb 23, 2021
Methods of treating developmental disorders and/or seizure disorders with etifoxine
OVID THERAPEUTICS INC0 citations62
US10870855B2Dec 22, 2020
Use of MIR101 or MIR128 in the treatment of seizure disorders
OVID THERAPEUTICS INC1 citations62
US10765666B2Sep 8, 2020
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
OVID THERAPEUTICS INC1 citations62
US10704048B2Jul 7, 2020
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
OVID THERAPEUTICS INC1 citations62
US10420773B2Sep 24, 2019
Methods of treating developmental disorders and/or seizure disorders with etifoxine
OVID THERAPEUTICS INC1 citations62
US12285397B2Apr 29, 2025
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
OVID THERAPEUTICS INC0 citations58
US11660277B2May 30, 2023
Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
OVID THERAPEUTICS INC0 citations58
US10493069B2Dec 3, 2019
Methods of treating behavioral syndromes using pipradrol
OVID THERAPEUTICS INC0 citations52
US10426746B2Oct 1, 2019
Methods of treating developmental disorders with biguanides
OVID THERAPEUTICS INC0 citations52
US10265300B2Apr 23, 2019
Methods of treating seizure disorders
OVID THERAPEUTICS INC0 citations52
US10123979B2Nov 13, 2018
Methods of treating developmental disorders with biguanides
OVID THERAPEUTICS INC1 citations52
Showing the top 50 of 51 patents by PatentIndex Score.